Skip to main content
. 2013 Dec 3;175(1):41–48. doi: 10.1111/cei.12209

Figure 1.

Figure 1

Tumour necrosis factor (TNF)-α blockade reduces the incidence and delays the onset of experimental autoimmune encephalomyelitis (EAE). (a) Clinical course of a representative cohort of Enbrel®-treated mice (white squares) and mice that received phosphate-buffered saline (PBS) (black circles) or Humira® injections (grey triangles). The Enbrel® and PBS cohort included mice that did not develop EAE. (b) Mean day of EAE onset (***P < 0·001, rank sum test). (c) EAE incidence with solid bar segments referring to diseased mice and dotted segments referring to healthy mice 20 days post-immunization (*P < 0·05, Fisher's exact test). (d) Mean score after EAE onset of all diseased mice. The data refer to n = 15 Enbrel®-, n = 10 Humira®- and n = 19 PBS-treated mice.